ArticleEuropean radiology2026
LI-RADS nonradiation treatment response assessment version 2024: diagnostic performance in HCC treated with transarterial chemoembolization.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
BACKGROUND AND
objectivesThe 2024 version of the Liver Imaging Reporting and Data System (LI-RADS) Treatment Response Assessment (TRA) introduces two distinct algorithms: nonradiation TRA and radiation TRA. We aimed to assess the diagnostic performance of LI-RADS v2024 nonradiation TRA in evaluating hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE).
methodsThis retrospective single-center study enrolled 167 patients (mean age, 59 years ± 10 (standard deviation), 136 men) with HCC who underwent TACE followed by surgery. Post-treatment contrast-enhanced MRI was independently evaluated by two radiologists using the LI-RADS 2024 nonradiation TRA algorithm. Histopathologic results (complete necrosis (44/191) vs. incomplete necrosis [147/191]) served as the reference standard. Sensitivity, specificity, and accuracy of LI-RADS Treatment Response (LR-TR) categories were calculated. The impact of ancillary features (AFs) on diagnostic performance was analyzed using the McNemar test.
resultsFor predicting incomplete necrosis, the LR-TR Viable category showed a sensitivity of 70.1% (95% CI: 0.63-0.77) and specificity of 97.7% (95% CI: 0.93-0.98). For predicting complete necrosis, the LR-TR Nonviable category demonstrated a sensitivity of 77.3% (95% CI: 0.65-0.90) and specificity of 81.0% (95% CI: 0.75-0.87). Incorporating AFs significantly improved sensitivity for detecting incomplete necrosis (77.6% vs. 70.1%, p = 0.003) without compromising specificity (88.6% vs. 97.7%, p = 0.134).
conclusionLI-RADS v2024 nonradiation TRA demonstrated good diagnostic performance in assessing HCC response after TACE. The use of AFs enhanced sensitivity for detecting residual viable tumors, supporting their clinical utility in equivocal cases. KEY POINTS: Question The diagnostic performance of the 2024 updated Liver Imaging Reporting and Data Systems (LI-RADS) Treatment Response Assessment (TRA), particularly the role of ancillary features (AFs), requires evaluation. Findings LI-RADS v2024 nonradiation TRA performed well in predicting histopathologic necrosis, with AFs significantly improving sensitivity for viability prediction. Clinical relevance The application of AFs is recommended to optimize post-TACE assessment and clinical decision-making for HCC management.
Indexed as
Identifiers
41071276What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.